Oxidative stress: A novel treatment target in psychiatric disorder

International Journal of Pharmaceutical Sciences Review and Research

Volumn 9, Issue 1, 2011, Pages 165-172

  Kumari, Reena ^a   Chatterjee, Manavi ^b   Singh, Seema ^b   Kaundal, Madhu ^a   Ashwalayan, V D ^a  

^a SHOBHIT UNIVERSITY   (India)

^b CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Antioxidants; Oxidative stress; Schizophrenia; Serotoninergic

Indexed keywords

ANTIOXIDANT; CATALASE; CERULOPLASMIN; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLUTAMIC ACID; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE TRANSFERASE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE;

APOPTOSIS; CARBOXYLATION; DISEASE COURSE; DNA DAMAGE; DRUG EFFECT; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME PHOSPHORYLATION; GLUTATHIONE METABOLISM; HUMAN; LIPID PEROXIDATION; MOLECULAR PATHOLOGY; NEUROTRANSMITTER RELEASE; OXIDATIVE STRESS; REVIEW; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SIGNAL TRANSDUCTION;

EID: 79960598896     PISSN: None     EISSN: 0976044X     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Lohr JB, Browning JA, Free radical involvement in neuropsychiatric illnesses, Psychopharmacol Bull, 31(1),1995, 159-165.
2. Akyol O, Zoroglu SS, Armutc F, Sahin S, Gurel A, Nitric oxide as a physiological factor in neuropsychiatric disorder, In Vivo, 18(3), 2004, 377-390.
3. Yao JK, Reddy RD, van Kammen DP, Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implication, CNS Drugs, 15, 2001, 287-310.
4. Taneli F, Pirildar S, Akdeniz F, Uyanik B. S, Ari Z, Serum nitric oxide metabolites levels and the effect of antipsychotic therapy in schizophrenia, Arch. Med. Res, 35(5), 2004, 401-405.
5. Seeman P, Dopamine receptor and dopamine hypothesis of schizophrenia, synapse, 1(2),1987, 133-52.
6. Carlsson A, The dopamine theory revisited. In: Hirsch SR, Weinberger DR, editor. Schizophrenia. Oxford: Blackwell sciences; 1995, 379-400.
7. Javitt DC, Zukin SR, Recent advances in the phencyclidine model of schizophrenia, American Journal of Psychiatry, 148(10),1991, 1301-1308.
8. Coyle JT, The gluaminergic dysfunction hypothesis for schizophrenia, Harv Rev Psychiatry, 3(5), 1996, 241-53.
9. Deutsch SI, Mastropaolo J, Schwartz BL, Ross RB, Morihisa JM, A " glutaminergic hypothesis" of schizophrenia. Rationale for pharmacotherapy with glycine, Clinical Neuropharmacology, 12(1),1989, 1-13.
10. Oleney JW, Farber NB, Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry, 52(12), 1995, 998-1007.
11. Costall B, Naylor RJ, Animal neuropharmacology and its prediction of clinical response. In: Hirsch SR, Weinberger DR, editor. Schizophrenia. Oxford: Blackwell Sciences, 1995, 401-24.
12. Harrison PJ, Burnet PW, The 5-HT2A (serotonin 2A) receptor gene in the aetiology, pathophysiology, pharmacotherapy of schizophrenia, J Psychopharmacol, 11(1), 1997, 18-20.
13. Kulig K, LSD, Emerg Med Clin North, Am, 8(5), 1990, 551-58
14. Penington NJ, Fox AP, Effect of LSD on calcium current in central 5-HT-containing neuron: 5-HT receptor ma play a role in hallucinogenesis, J Pharmacol Exp Ther, 269(3), 1994, 1160-1165.
15. Jalpha K, Koch M, Picrotoxix in the medial prefrontal cortex impair sensorimoter gating in rats: reversal by haloperidol, Psychopharmacology, 144(4), 1999, 347-54.
16. Goldman-Rakic PS, Selemon LD, Functional and anatomical aspects of prefronnta pathology in schizophrenia, Schizophr bull, 23(3), 1997, 437-58.
17. Lewis DA, Pierri JN, Volk DW, Melchitzky DS, Woo TU, Altered GABA neurotransmission and prefrontal cortical cortical dysfunction in schizophrenia, Biol Psychiatry, 46(5), 1999, 616-26.
18. Lewis DA, GABAergic local circuit neuron and prefrontal cortical dysfunction in schizophrenia, Brain Res Brain Res Rev, 31(2-3), 2003, 270-6.
19. Suzuki E, Nakaki T, Nakamura M, Miyaoka H. Plasma nitrite level in deficit versus non-deficit forms of schizophrenia, J. Psychiatry. Neurosci, 28(4), 2003, 288-292.
20. Ramirez J, Garnica R, Bolt MC, Montes S, Rios C, Low concentration of nitrite and nitrate in the cerebrospinal fluid from schizophrenic patients: a pilot study, Schizophr. Res, 68(2-3), 2004, 357-361.
21. Yao JK, Reddy RD, van Kammen DP, Human plasma glutathione peroxidase and symptom severity in schizophrenia, Biol Psychiatry, 45, 1999, 1512-1515.
22. Valko M, Leibfritz D, Moncol J, Mazur M, Telser J, Free radicals and antioxidants in normal physiological functions and human disease, The International Journal of Biochemistry & Cell Biology 39, 2007, 44-84
23. Berk M, Ng F, Dean O, Dodd S, Bush AI, Glutathione; a novel treatment target in psychiatry, Trends in pharmacological sciences, 29, 2008, 346-351
24. Srivastava, N, Barthwal MK, Dalal PK, Agarwal, Srimal RC, Seth PK, Dikshit M, Nitrite content and antioxidant enzyme levels in the blood of schizophrenia patients, Psychopharmacology (Berl), 158, 2001, 140-145.
25. Ben Othmen L, Mechri A, Fendri C, Bost M, Chazot G, Gaha L, Kerkeni A, Altered antioxidant defense system in clinically stable patients with schizophrenia and their unaffected siblings, Prog Neuropsychopharmacol Biol Psychiatry, 32, 2008, 155-159.
26. Herken, H, Uz E, Ozyurt H, Sogut S, Virit O, Akyol O, Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia, Mol Psychiatry, 6, 2001, 66-73.
27. Grima, G, Benz B, Do KQ, Glial-derived arginine, the nitric oxide precursor, protects neurons from NMDA-induced excitotoxicit,. Eur J Neurosci, 14, 2001, 1762-1770.
28. Nakao, S, Nagata A, Miyamoto E, Masuzawa M, Murayama T, Shingu K, Inhibitory effect of propofol on ketamine-induced c-Fos expression in the rat posterior cingulate and retrosplenial cortices is mediated by GABAA receptor activation, Acta Anaesthesiol Scand, 47, 2003, 284-290.
29. Akyol, O, Herken H, Uz E, Fadillioglu E, Unal S, Sogut S, Ozyurt H, Savas HA, The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance, Prog Neuropsychopharmacol Biol Psychiatry, 26, 2002, 995-1005.
30. Andreazza AC, Cassini C, Rosa AR, Leite MC, de Almeida LM, Nardin P, Cunha AB, Cereser KM, Santin A, Gottfried C, Salvador M, Kapczinski F, Goncalves CA, Serum S100B and antioxidant enzymes in bipolar patients, J Psychiatr Res, 41, 2007, 523-529.
31. Herken, H, Gurel A, Selek S, Armutcu F, Ozen ME, Bulut M, Kap O, Yumru M, Savas HA, Akyol O, Adenosine deaminase, nitric oxide, superoxide dismutase, and xanthine oxidase in patients with major depression: impact of antidepressant treatment, Arch Med Res, 38, 2007, 247-252.
32. Machado-Vieira, R, Andreazza AC, Viale CI, Zanatto V, Cereser V, da Silva Vargas R, Kapczinski F, Portela LV, Souza DO, Salvador M, Gentil V, Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects, Neurosci Lett, 421, 2007, 33-36.
33. Bal-Price, A, Brown GC, Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity, J Neurosci, 21, 2001, 6480-6491.
34. Brown, GC, Cooper CE, Nanomolar concentrations of nitric oxide reversibly inhibit synaptosomal respiration by competing with oxygen at cytochrome oxidase, FEBS Lett, 356, 1994, 295-298.
35. McNaught, KS, Brown GC, Nitric oxide causes glutamate release from brain synaptosomes, J Neurochem, 70, 1998, 1541-1546.
36. Stewart VC, Heslegrave AJ, Brown GC, Clark JB, Heales SJ, Nitric oxide-dependent damage to neuronal mitochondria involves the NMDA receptor, Eur J Neurosci, 15, 2202, 458-464.
37. Golde S, Chandran S, Brown GC, Compston A, Different pathways for iNOS-mediated toxicity in vitro dependent on neuronal maturation and NMDA receptor expression, J Neurochem, 82, 2002, 269-282
38. Bal-Price A, Moneer Z, Brown GC, Nitric oxide induces rapid, calcium-dependent release of vesicular glutamate and ATP from cultured rat astrocytes, Glia, 40, 2002, 312-323
39. Moghaddam B, Adams B, Verma A, Daly D, Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex, J Neurosci, 17, 1997, 2921-2927.
40. Nakao S, Nagata A, Miyamoto E, Masuzawa M, Murayama T, Shingu K, Inhibitory effect of propofol on ketamineinduced c-Fos expression in the rat posterior cingulate and retrosplenial cortices is mediated by GABAA receptor activation, Acta Anaesthesiol Scand, 47, 2003, 284-290.
41. Duncan GE, Moy SS, Knapp DJ, Mueller RA, Breese GR. Metabolic mapping of the rat brain after subanesthetic doses of ketamine: potential relevance to schizophrenia, Brain Res, 787, 1998, 181-190.
42. Lorrain DS, Baccei CS, Bristow LJ, Anderson JJ, Varney MA, Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268, Neuroscience, 117, 2003, 697-706.
43. Berk M, Dodd S, Kauer-Sant'anna M, Malhi GS, Bourin M, Kapczinski F, Norman T, Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder, Acta Psychiatr Scand Suppl, 2007, 41-49.
44. Rukmini R, Shanmugam VM, Saxena P, Gokhale RS, Sankaranarayanan R, Crystallization and preliminary X-ray crystallographic investigations of an unusual type III polyketide synthase PKS18 from Mycobacterium tuberculosis, Acta Crystallogr D Biol Crystallogr, 60, 2004, 749-751.
45. Smith, CD, Carney JM, Starke-Reed PE, Oliver CN, Stadtman ER, Floyd RA, Markesbery WR, Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease, Proc Natl Acad Sci U S A, 88, 1991, 10540-10543.
46. Abdalla DS, Monteiro HP, Oliveira JA, Bechara EJ, Activities of superoxide dismutase and glutathione peroxidase in schizophrenic and manic-depressive patients, Clin Chem, 32, 1986, 805-807.
47. Halliwell B, Oxidants and the central nervous system: some fundamental questions. Is oxidant damage relevant to Parkinson's disease, Alzheimer's disease, traumatic injury or stroke? Acta Neurol Scand Suppl, 126, 1989, 23-33.
48. Reddy R, Sahebarao MP, Mukherjee S, Murthy JN, Enzymes of the antioxidant defense system in chronic schizophrenic patients, Biol Psychiatry, 30, 1991, 409-412.
49. Sullivan JM, Traynelis SF, Chen HS, Escobar W, Heinemann SF, Lipton S, Identification of two cysteine residues that are required for redox modulation of the NMDA subtype of glutamate receptor, Neuron, 13, 1994, 929-936.
50. Kohr G, Eckardt S, Luddens H, Monyer H, Seeburg PH, NMDA receptor channels: subunit-specific potentiation by reducing agents, Neuron, 12, 1994, 1031-1040.
51. Zangerle L, Cuenod M, Winterhalter KH, Do KQ. Screening of thiol compounds: depolarization-induced release of glutathione and cysteine from rat brain slices, J Neurochem, 59, 1992, 181-189.
52. Meister A, Transport and metabolism of glutathione and gamma-glutamyl amino acids, Biochem Soc Trans, 11, 1983, 793-794.
53. Schafer FQ, Buettner GR, Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple, Free Radic Biol Med, 30, 2001, 1191-1212.
54. Pantelis, C, Yucel M, Wood SJ, Velakoulis D, Sun D, Berger G, Stuart GW, Yung A, Phillips L, McGorry PD, Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia, Schizophr Bull, 31, 2005, 672-696.